For the quarter ending 2026-03-31, MCRB had -$15,932K decrease in cash & cash equivalents over the period. -$16,360K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net (accretion) amortization of (discounts) premiums on investments | - | 0 | - | - |
| Gain on sale of vowst business, net of transaction costs | - | 0 | 0 | - |
| Amortization of debt issuance costs | - | 0 | 0 | 0 |
| Net (loss) income | -19,913 | -15,335 | 8,204 | 12,827 |
| Loss associated with extinguishment of debt | - | 0 | 0 | - |
| (gain)/loss on disposal of fixed assets | - | 192 | 0 | 0 |
| Impairment of long-lived assets | - | 0 | 0 | 0 |
| Change in fair value of warrant liabilities | - | 0 | 0 | 0 |
| Stock-based compensation expense | 1,766 | 3,199 | 2,482 | 5,159 |
| Depreciation and amortization expense | 781 | 954 | 1,044 | 2,135 |
| Collaboration (profit) loss sharing - related party | - | 0 | - | - |
| Non-cash operating lease cost | 2,255 | 2,186 | 2,125 | 4,109 |
| Accounts receivable due from spn - related party | -360 | -66 | -456 | -1,186 |
| Accounts receivable | 76 | -194 | 351 | - |
| Prepaid expenses and other current and other non-current assets | 1,323 | 19 | -688 | 3,389 |
| Collaboration receivable - related party | - | 0 | 0 | 0 |
| Inventories | - | 0 | 0 | 0 |
| Deferred income - related party | - | 0 | 0 | 0 |
| Deferred revenue - related party | - | 0 | - | - |
| Accounts payable | 656 | 5 | -515 | -1,887 |
| Accrued liabilities due to spn - related party | 0 | 1,172 | 9,003 | 4,297 |
| Operating lease liabilities | -2,467 | -2,287 | -2,181 | -4,206 |
| Accrued expenses and other current and long-term liabilities | -1,045 | -2,347 | 633 | -4,794 |
| Net cash (used in) provided by operating activities | -16,360 | -14,710 | 2,206 | 13,621 |
| Purchases of property and equipment | 0 | 29 | 8 | 215 |
| Proceeds from sales of property and equipment | - | 210 | - | - |
| Purchases of investments | - | 0 | - | - |
| Sales and maturities of investments | - | 0 | - | - |
| Sales of restricted investments | - | 0 | 0 | 0 |
| Proceeds from sale of vowst business | - | 0 | 0 | - |
| Net cash (used in) investing activities | 0 | 181 | -8 | -215 |
| Proceeds from at the market equity offering, net of issuance costs | 400 | 12,171 | 0 | 996 |
| Proceeds from exercise of stock options | - | 486 | 15 | - |
| Proceeds from securities purchase agreement - related party | - | 0 | 0 | - |
| Issuance of common stock under espp | 28 | 0 | 46 | 184 |
| Proceeds from issuance of debt, net of issuance costs | - | 0 | - | - |
| Repayment of notes payable | - | 0 | 0 | - |
| Net cash provided by financing activities | 428 | 12,657 | 61 | 1,180 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | -15,932 | -1,872 | 2,259 | 14,586 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | - | 0 | - | - |
| Cash, cash equivalents and restricted cash at beginning of period | 54,434 | 56,306 | 39,461 | - |
| Cash, cash equivalents and restricted cash at end of period | 38,502 | 54,434 | 56,306 | - |
Seres Therapeutics, Inc. (MCRB)
Seres Therapeutics, Inc. (MCRB)